Candela Laser Approved for Treatment of Periorbital Wrinkles
WAYLAND, Mass., Feb. 13 -- Candela Corp. has received FDA clearance from the US Food and Drug Administration to market the Vbeam pulsed dye laser for treatment of periorbital wrinkles.
"We're excited that this new clearance validates the anecdotal feedback we've been receiving virtually since the Vbeam's introduction two years ago -- namely, that this laser has exceptional utility in the treatment of periorbital wrinkles," said Gerard E. Puorro, Candela president and CEO.
"The FDA clearance can increase physicians' confidence in the Vbeam not only as an important laser for the medical treatment of vascular lesions, but as a laser for periorbital wrinkle reduction. We feel this new clearance confirms the Vbeam's versatility and utility as a staple in the physician's office," Puorro said.
LATEST NEWS
- CLEO Heads to the East Coast
Apr 29, 2024
- Laser-Based Gas Analyzer Developed to Detect Air Pollution
Apr 29, 2024
- Qubits Could be Stored in Flash-Like Memory
Apr 29, 2024
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024